リウマトレックスカプセル２ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00563 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 100 |
| 日本商品名（例） | メトトレキサートカプセル２ｍｇ「サワイ」, メトトレキサートカプセル２ｍｇ「サンド」, メトトレキサートカプセル２ｍｇ「トーワ」 |
承認適応症（KEGG）
慢性リンパ性白血病、慢性骨髄性白血病、絨毛癌、乳癌、尿路上皮癌、骨肉腫、胃癌、関節リウマチ、尋常性乾癬、関節症性乾癬、膿疱性乾癬、乾癬性紅皮症、若年性特発性関節炎
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | mycosis fungoides and variants | 99% | DL |
| 2 | acute lymphoblastic/lymphocytic leukemia | 99% | DL |
| 3 | folliculotropic mycosis fungoides | 99% | DL |
| 4 | acute lymphoblastic leukemia (disease) | 99% | DL |
| 5 | rheumatoid arthritis | 99% | DL |
| 6 | pulmonary blastoma | 99% | DL |
| 7 | primary pulmonary lymphoma | 99% | DL |
| 8 | small cell lung carcinoma | 99% | DL |
| 9 | well-differentiated fetal adenocarcinoma of the lung | 99% | DL |
| 10 | Hodgkins lymphoma | 99% | DL |
| 11 | rhabdomyosarcoma (disease) | 99% | DL |
| 12 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99% | DL |
| 13 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99% | DL |
| 14 | parameningeal embryonal rhabdomyosarcoma | 99% | DL |
| 15 | botryoid-type embryonal rhabdomyosarcoma of the vagina | 99% | DL |
| 16 | embryonal extrahepatic bile duct rhabdomyosarcoma | 99% | DL |
| 17 | extrahepatic bile duct rhabdomyosarcoma | 99% | DL |
| 18 | prostate embryonal rhabdomyosarcoma | 99% | DL |
| 19 | brachydactyly-syndactyly syndrome | 99% | DL |
| 20 | Burkitt lymphoma | 98% | DL |
| 21 | leukemia, lymphocytic, susceptibility to | 98% | DL |
| 22 | liver sarcoma | 98% | DL |
| 23 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 98% | DL |
| 24 | unclassified myelodysplastic syndrome | 98% | DL |
| 25 | aregenerative anemia | 98% | DL |
| 26 | refractory cytopenia of childhood | 98% | DL |
| 27 | severe congenital hypochromic anemia with ringed sideroblasts | 98% | DL |
| 28 | partial deletion of the long arm of chromosome 5 | 98% | DL |
| 29 | myelodysplastic syndrome | 98% | DL |
| 30 | acute lymphoblastic leukemia | 98% | DL |
| 31 | granulomatous slack skin disease | 97% | DL |
| 32 | myeloid leukemia | 97% | DL |
| 33 | ALK-positive large B-cell lymphoma | 97% | DL |
| 34 | precursor lymphoblastic lymphoma/leukemia | 97% | DL |
| 35 | obsolete Hodgkin's granuloma | 97% | DL |
| 36 | ganglioneuroblastoma (disease) | 97% | DL |
| 37 | lymphosarcoma | 96% | DL |
| 38 | localized pagetoid reticulosis | 96% | DL |
| 39 | small intestine lymphoma | 96% | DL |
| 40 | adenosarcoma | 96% | DL |
| 41 | neuroblastoma | 96% | DL |
| 42 | monocytic leukemia | 96% | DL |
| 43 | classic Hodgkin lymphoma | 96% | DL |
| 44 | lymphoid neoplasm | 96% | DL |
| 45 | neonatal jaundice | 96% | DL |
| 46 | ectodermal dysplasia and immunodeficiency | 96% | DL |
| 47 | classic Hodgkin lymphoma, lymphocyte-depleted type | 96% | DL |
| 48 | retroperitoneal neoplasm | 96% | DL |
| 49 | systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood | 96% | DL |
| 50 | lung mixed small cell and squamous cell carcinoma | 96% | DL |
（上位50件を表示。全100件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。